menu

Patient Case Review: Nebulized Therapy for Maintenance Treatment of COPD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Patient Case Review: Nebulized Therapy for Maintenance Treatment of COPD

Program Information
Recommended

Program Information

ReachMD Healthcare Image
RestartResume

Explore the treatment strategies available for those struggling with persistent or worsening symptoms of COPD through the lens of a patient case.

  • Sponsored by

  • Overview

    Meet David, a 57-year-old male and former smoker with a 50-year smoking history who’s beginning to experience worsening symptoms of chronic obstructive pulmonary disease (COPD). Here to walk us through David’s case and discuss whether or not he is a candidate for YUPELRI as a maintenance treatment option for COPD is Dr. Aaron Milstone, pulmonologist at Williamson Medical Center.

    Case based on real patient. Patient's name has been changed. Image is actor portrayal.

    Dr. Milstone is a paid consultant of Mylan Specialty L.P., a Viatris Company, and Theravance BioPharma US,
    Inc.

    VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris Company. THERAVANCE BIOPHARMA®, THERAVANCE®, and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).

    © 2022 Viatris Inc. All Rights Reserved. REV-2022-0020

  • INDICATION

    YUPELRI® inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

  • IMPORTANT SAFETY INFORMATION

    YUPELRI is contraindicated in patients with hypersensitivity to revefenacin or any component of this product.

    YUPELRI should not be initiated in patients during acutely deteriorating or potentially life-threatening episodes of COPD, or for the relief of acute symptoms, such as a rescue therapy for the treatment of acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta2-agonist.

    As with other inhaled medicines, YUPELRI can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs following dosing with YUPELRI, it should be treated immediately with an inhaled, short-acting bronchodilator. YUPELRI should be discontinued immediately, and alternative therapy should be instituted.

    YUPELRI should be used with caution in patients with narrow-angle glaucoma. Patients should be instructed to immediately consult their healthcare provider if they develop any signs and symptoms of acute narrow-angle glaucoma, including eye pain or discomfort, blurred vision, visual halos, or colored images in association with red eyes from conjunctival congestion and corneal edema.

    Worsening of urinary retention may occur. Use with caution in patients with prostatic hyperplasia or bladder-neck obstruction and instruct patients to contact a healthcare provider immediately if symptoms occur.

    Immediate hypersensitivity reactions may occur after administration of YUPELRI. If a reaction occurs, YUPELRI should be stopped at once and alternative treatments considered.

    The most common adverse reactions occurring in clinical trials at an incidence greater than or equal to 2% in the YUPELRI group, and higher than placebo, included cough, nasopharyngitis, upper respiratory infection, headache and back pain.

    Coadministration of anticholinergic medicines or OATP1B1 and OATP1B3 inhibitors with YUPELRI is not recommended.

    YUPELRI is not recommended in patients with any degree of hepatic impairment.

    Please see accompanying Full Prescribing Information.

    For additional information please contact us at 1-800-395-3376.

Schedule5 Dec 2022